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It is known that tumors progression is manifested in 
three main directions — enhancement of invasion�� me­
tastasis�� and formation of drug resistance. Metastasis 
is the main cause of mortality of oncological patients. 
At the same time drug resistance of tumor results in 
low efficacy оf anticancer agents and continues to �e a 
major and largely unsolved pro�lem of cancer therapy. 
Despite the availa�ility of approximately 6� different 
agents for the systemic therapy of cancer�� resistance 
to treatment is developed in the majority of cases. 
Presently it is well documented that progression of 
malignant tumors can’t occur without tumor angiogen­
esis. According to common point of view�� higher stages 
of disease progression are linked to more intense pro­
cesses of angiogenesis [��� �]. For example�� in a num­
�er of solid tumors there has �een shown a relationship 
�etween clinical stages of cancer and angiogenic 
potential of tumor�� which was evaluated or �y the level 
of circulating VEGF�� or/and �y the level of its expres­
sion in tumor tissue�� and/or �y the density of vessels in 
tumor [3�8]. At the same time some researchers have 
documented the a�sence of such correlation [��� ��]. 
The am�iguous results on direct correlation �etween 
tumor progression and angiogenesis were o�tained 
also in preclinical and clinical trials on anticancer ac­
tion of antiangiogenic agents [��]. �uch am�iguous­
ness is caused �y wide varia�ility of pathophysiologic 
characteristics of cancer process�� complicating the 
determination of the stage of tumor progression in 
the conditions of clinical study and making practically 
impossi�le the esta�lishment of correlation �etween 
tumor progression and angiogenesis. Confirmations 
of the existence �or a�sence�� of the relations �etween 
progression of tumor and its neovascularization could 
�e o�tained only in experimental studies �ased on the 
use of tumor models of similar genesis�� �ut characteri­
zed �y different stage of progression. 
That’s why the aim of the present research was 
to study the relation �etween angiogenic potential of 
tumor and a�undance of tumor growth using the model 
of Lewis lung carcinoma �LLC�� with different degree of 
resistance to cisplatin �cis­DDP��. 
In the study�� parental LLC�� and its two variants 
�LLC­� и LLC­������ o�tained at �th and ��th stage of 
experimental LLC progression toward formation of the 
resistance to cis­DDP in vivo were used. The changes 
of angiogenic potential upon tumor progression were 
evaluated �y the level of production of VEGF �y the 
primary cultures of LLC�� LLC­� and LLC­�� in vitro�� 
and also �y the dynamics of alteration of circulating 
VEGF during the growth of tumors in vivo.
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Aim: To study the relationship between tumor angiogenic potential and its growth and metastasis using Lewis lung carcinoma (LLC) 
models with different degree of resistance to cis-diamminedichloroplatinum (cis-DDP). Methods: LLC and its two cis-DDP-resistant 
variants (LLC-9 и LLC-19), were used. For determination of angiogenic potential of LLC, LLC-9 and LLC-19, the level of VEGF 
production by these tumor cells in vitro and the level of circulating VEGF during tumor growth in vivo was measured by enzyme-linked 
immunosorbent assay. Results: Progressive decrease of LLC-9 and LLC-19 sensitivity to action of cis-DDP evidenced in vitro (IC50 = 
0.0077 ± 0.0005 mg/ml and 0.0156 ± 0.0008 mg/ml respectively vs. 0.004 ± 0.0003 mg/ml for LLC, p < 0.05) and in vivo (index of 
primary tumor growth inhibition by cis-DDP was 26% and 3% respectively vs. 46%; index of metastasis inhibition — 46% and 11% vs. 
65%, p < 0.05) was accompanied by the significant changes of tumor angiogenic potential. The level of VEGF production by primary 
culture of LLC-9 in vitro was 1.5 fold higher (p < 0.05) than that by primary culture of LLC, whereas there were no differences in the 
level of VEGF production between LLC-19 and LLC. The level of circulating VEGF drastically increased in the initial phase of LLC-9 
and LLC-19 growth in vivo, whereas in LLC bearing mice the dynamic changes of VEGF level are characterized by the presence of 
long-term latent period (tlag = 17.0 ± 0.3 days). In LLC bearing mice the character of changes of circulating VEGF level significantly 
correlated with the number of metastases (p < 0.001) but not with tumor volume; while in LLC-9 bearing mice — with tumor volume 
(p < 0.01) and the number of metastases (p < 0.05). Although maximum level of circulating VEGF was significantly (p < 0.05) higher 
in LLC-9 bearing mice than that in LLC bearing mice, maximum number of lung metastases was significantly (p < 0.05) lower in 
LLC-9 bearing mice vs LLC. In contrast to LLC-9, in LLC-19 bearing mice the level of metastatic injury was significantly elevated 
(p < 0.05) and the level of circulating VEGF considerably correlated with both tumor volume (p < 0.01) and metastatic index (p < 
0.01). Conclusion: There is revealed a direct correlation between the level of circulating VEGF and all parameters of tumor progression 
observed only in the cases of highly resistant tumors, whilst elevation of circulating VEGF level during tumor growth in vivo could be 
considered as a marker of metastasis not dependent on a drug resistance of tumor. 
Key Words: VEGF, Lewis lung carcinoma, cis-DDP resistance.
Received: July 2, 2007. 
*Correspondence: E-mail: gis@onconet.kiev.ua 
Abbreviation used: cis-DDP — cis-diamminedichloroplatinum; 
LLC — Lewis lung carcinoma.
Exp Oncol ����
���� 3�� �������
��8 Experimental Oncology ���� ��������� ���� ��eptem�er��
MATERIALS AND METHODS
Experimental animals and tumor strains. The 
investigation was carried out in C5�Bl/6 female mice 
weighing ����3 g aged � to �.5 months from the viva­
rium of R.E. Kavetsky Institute of experimental patholo­
gy�� oncology and radio�iology of National Academy of 
�ciences of Ukraine �IEPOR��. All investigations with 
animals were performed according to rules prepared 
animal �y the Bioethical Committee of IEPOR.
As an experimental tumor model�� Lewis lung car­
cinoma �LLC�� National Bank of Cell Lines and Tumor 
�trains�� IEPOR�� and its two variants �LLC­��� LLC­���� 
developed upon �th and ��th cycle of experimental LLC 
progression towards the formation of drug resistance to 
action of cis­DDP in vivo�� were used. Experimental design 
of tumor progression was as follows. On the �st cycle of 
formation of drug resistance to action of cis­DDP the 
tumor cell suspension �� х ��6 / �.� ml of Haenk’s solu­
tion�� which was o�tained from LLC primary tumor tissues 
�y routine procedure of trypsinization was inoculated 
intramusculary into mice. After tumor cell inoculation 
mice were divided into experimental and control groups 
�not less than 8 animals in each��. Mice of experimental 
group recieved the course of chemotherapy with cis­DDP 
�5 injections at the total dose of 6.� mg/kg of �ody weight 
every second day starting from �th day after tumor cell 
inoculation��. The tumor relapsed after chemotherapy was 
used to prepare the tumor cell suspension for inoculation 
into mice with the aim to carry out the following cycle of 
tumor progression. 
The �nd and following cycles were identical to the �st 
one. A total of �� cycles of LLC passage in mice and 
retreatment of tumor �earing mice with cis­DDP were 
performed. At every cycle of experimental progression 
the kinetics of primary tumor growth and its metastatic 
spreading were studied �y routine methods.
For evaluation of the sensitivity of LLC, LLC-9 
and LLC-19 to action of cis-DDP in vivo indexes of 
inhi�ition of tumor growth �GI�� and metastasis �MI�� 
were calculated using following formulas:
                   V0 – VGI = 100 × ————— ����                       V0
                   N0 – NMI = 100 × ————— ����
                        N0
where V0, N0 — mean values of tumor volume and 
num�er of metastases �correspondingly�� in control 
groups and V, N — mean values of tumor volume and 
num�er of metastases �correspondingly�� in experi­
mental groups. The estimations were carried out on 
�th day after chemotherapy completion. 
The sensitivity of LLC, LLC-9 and LLC-19 cells 
to action of cis-DDP in vitro were determined us­
ing tumor cells o�tained �y trypsinization of primary 
tumor tissues removed on �8���th day after tumor cell 
inoculation �primary cultures��. IC5� �the concentration 
of cytostatic agent resulted in 5�% cellular death�� cal­
culated from data o�tained in short­term cytotoxic test�� 
was used as a value of sensitivity of tumor cells to action 
of cis­DDP. For that purpose�� ��5 via�le cells/well in ���� 
ml RPMI �64� medium ��igma�� U�A�� supplemented 
with � mM glutamine�� ��% fetal �ovine serum ��igma�� 
U�A�� and 4� μg/ml gentamicine were plated in tripli­
cate into �6­well plates �Nunclon�� Denmark��. After 3 h 
of pre­incu�ation of tumor cells at 3� °C in humidified 
atmosphere containing 5% CO��� �.� ml medium con­
taining cis­DDP in progressively reducing concentration 
ranging from �.5 mg/ml to �.���5 mg/ml was added in 
each well. After �4 h of tumor cell exposition to cis­DDP 
or without it �control���� the num�er of via�le cells/well 
was evaluated �y MTT­test [��]. 
The level of VEGF production by primary cul-
tures of LLC, LLC-9 and LLC-19 was determined af­
ter their �4 h incu�ation in vitro in RPMI �64� complete 
medium under standard conditions. Tumor cells at the 
density of � х ��5 via�le cells/well in �.� ml complete 
medium were plated into �6­well plate and �4 h later 
the aliquotes of medium were collected and the num­
�er of tumor cells was evaluated �y measurement of 
via�le cells/well �y MTT­test �expressed in units of ex­
tinction��. The VEGF concentration in medium samples 
was measured �y enzyme­linked immunosor�ent 
assay �ELI�A�� mouse VEGF kits �R & D�� GBn�� accord­
ing to the manufacturer’s protocol. The level of VEGF 
production was recalculated per cell and represented 
in relative units according to following formula:
VEGF = VEGFP / Nex
where VEGFP — the total VEGF level in each me­
dium sample �pg/ml���� Nex — the num�er of via�le 
cells/well in units of extinction. 
During LLC, LLC-9 and LLC-19 growth the level 
of circulating VEGF was determined using ELI�A 
mouse VEGF kits �R & D�� according to the manufac­
turer’s protocol.
The dynamic changes of the level of circulating 
VEGF in tumor �earing mice during tumor growth was 
analyzed �y Wei�ul’s model:
VEGF = VEGF� × exp�a × �t � tlag��
����� �3��
where the parameter α reflects the maximal level of 
VEGF production ��y tumor cells and/or other cells of 
host organism��; the parameter β reflects the kinetics 
of VEGF level inhi�ition as a result of either decreasing 
of the num�er of VEGF­secreted cells or the activation 
of antiangiogenic processes. The parameter tlag ex­
presses a delay in the level of circulating VEGF; VEGF0 
is the level of circulating VEGF in intact animals. 
The parameters of the model for all variants of 
LLC were determined from the �est fit of mathemati­
cal model �3�� to experimental data using nonlinear 
regression analysis. 
The growth kinetics of primary tumors as well as 
total num�er and volume of lung metastases in tumor 
�earing mice were evaluated �y routine methods. The 
portion of metastases in vascular phase was calculated 
considering that diameter of metastases in vascular 
phase is greater than �.� mm.
The statistical analysis of the results was per­
formed using descriptive methods�� t­test�� correlation 
analysis and nonlinear regressive analysis. 
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RESULTS AND DISCUSSION
Sensitivity of LLC, LLC-9 and LLC-19 to the action 
of cis-DDP. As one may see in Ta�le ��� experimental 
progression of LLC toward formation of the resistance to 
the action of cis­DDP was accompanied �y progressing 
statistically significant decrease of antitumor and anti­
metastatic action of cis­DDP. In particular�� administration 
of cis­DDP to mice �earing parental LLC strain resulted 
in the decrease of the volume of primary tumor and the 
num�er of lung metastases �y 46 and 65% respectively�� 
compared to control group. The response of LLC­� and 
LLC­�� to administration of the drug was weaker com­
pared to that of LLC: for LLC­��� the percent of tumor 
growth inhi�ition and the level of metastasis was �6 and 
46%�� respectively�� �eing �.8­fold �p < �.�5�� and �.4­fold 
�p < �.�5�� lower than those in the case of parental LLC. In 
the case of LLC­���� antitumor and antimetastatic activity 
of cis­DDP was extremely low: the percent of primary 
tumor growth inhi�ition did not exceed 3%�� whilst the 
num�er of metastases decreased only �y ��% compared 
to respective indexes in LLC­��­�earing mice that did not 
receive cis­DDP treatment. 
Table 1. The sensitivity of LLC, LLC-9 and LLC-19 to action of cis-DDP in vivo
Tumor variant Group of mice Tumor size (mm) Number of lung metastases
LLC control 14.0 ± 0.3 24.3 ± 2.1
cis-DDP 7.6 ± 0.5* 8.6 ± 0.9*
LLC-9 control 14.5 ± 0.6 20.2 ± 1.4
cis-DDP 10.7 ± 0.6* 10.8 ± 0.6*
LLC-19 control 13.5 ± 0.5 27.5 ± 2.7
cis-DDP 11.5 ± 0.8 20.4 ± 1.3
*p < 0.01 vs corresponding value in control.
�imilar results were o�tained upon analysis of the 
sensitivity of LLC�� LLC­� and LLC­�� cells to the action of 
cis­DDP in vitro �Ta�le ���. The sensitivity of the primary 
culture of parental LLC to cis­DDP action evaluated �y 
IC5� value in short­term cytotoxic test in vitro�� was equal 
to �.��4 ± �.���3 mg/ml�� whilst that of the primary 
culture of LLC­� was practically twice higher �p < �.�5�� 
than that of LLC; for the primary culture of LLC­���� IC5� 
was nearly 4­fold �p < �.�5�� and �­fold �p < �.�5�� higher 
than those for LLC and LLC­� cells�� respectively. 
Table 2. The sensitivity of LLC, LLC-9 and LLC-19 to action of cis-DDP in vitro
Tumor variant IC50 (mg/ml)
LLC 0.004 ± 0.0003
LLC-9 0.0077 ± 0.0005*
LLC-19 0.0156 ± 0.0008*, **
*, **p < 0.05 vs LLC and LLC-9 correspondingly.
Production of VEGF by LLC, LLC-9 and LLC-19 
cells in vitro. It has �een revealed that at different 
stages of LLC progression�� the a�ility of tumor cells to 
produce VEGF�� evaluated �y the level of production of 
the factor �y the primary cultures during the first day of 
their incu�ation in vitro, varied significantly�� and these 
changes possess non­monotonous character. The for­
mation of drug resistance of LLC was characterized �y 
nearly dou�le �р < �.�5�� increase of VEGF production �y 
LLC­� cells with the next decrease of this index toward 
the level typical for parental LLC cells �Fig. ���. 
The level of circulating VEGF in animals bearing 
LLC, LLC-9 and LLC-19. In the process of progression 
of LLC toward formation of drug resistance to cis­DDP�� 
significant differences in the dynamics of alteration of 
circulating VEGF level were o�served �Fig. ��� Ta�le 3��. In 
animals �earing LLC­� and LLC­�� at early stages of tu­
mor growth�� the sharp elevation of the level of circulating 
VEGF has �een registered; at the same time the dynamics 
of alteration of circulating VEGF level in LLC­�earing mice 
was characterized �y significant latent period �tlag = ��.� ± 
�.3 days�� Ta�le 3��. The increase of VEGF level in �lood 
serum of LLC­�earing animals coincided with exponential 
phase of tumor growth. In the case of LLC­� and LLC­���� 
significant elevation of the level of circulating factor has 
�een o�served at the latent phase of tumor growth when 
the formation of tumor nodule from separate tumor cells 
occurs. It was interesting to note that the dynamics of 
alteration of circulating VEGF level �at the periods larger 
than tlag�� in �lood serum of LLC­�earing animals practi­
cally did not differ from that in LLC­��­�earing mice: 
there was no statistically significant differences in the 
parameters α and β �see Ta�le 3��. 
Fig. 1. The level of VEGF production �y primary cultures of LLC�� 
LLC­� and LLC­�� in vitro �values are expressed in percentages 
from corresponding value for LLC��
Fig. 2. The dynamic changes of the level of circulating VEGF dur­
ing LLC�� LLC­� and LLC­�� growth in vivo �values are expressed 
in percentages from the level of VEGF from intact mice��.
Table 3. Model parameters of the dynamic changes of circulating VEGF 
during LLC, LLC-9 and LLC-19 growth in vivo
Tumor variant Model parametersα (days-β) β tlag (days)
LLC 1.66 ± 0.15 0.2 ± 0.036 17.0 ± 0.3
LLC-9 2.1 ± 0.07* 0.08 ± 0.01* 0.0 ± 0.0*
LLC-19 1.68 ± 0.02** 0.18 ± 0.004** 0.1 ± 0.1*
*, **p < 0.01 vs LLC and LLC-R9 correspondingly.
During LLC­� growth�� the character of alteration of cir­
culating VEGF level was significantly different from these 
for LLC and LLC­���� evidenced �y statistically significant 
�p < �.���� differences in the parameters α and β �see 
Ta�le 3�� �etween LLC and LLC­��� and also �etween LLC 
and LLC­��. At the initial stages of LLC­� growth�� vigor­
ous �compared to two other LLC variants�� elevation of the 
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level of circulating VEGF�� reflected in α value that was �y 
�5% higher in LLC­� than those for LLC and LLC­��. This 
result is in good accordance with the data of comparative 
study of VEGF production �y LLC cells with the different 
degree of drug resistance �see Fig. ���. 
Contrary to the dynamics of VEGF level alteration in 
mice with LLC and LLC­�� characterized �y constant 
progressing elevation of the level of circulating factor in 
�lood serum�� vigorous rise of VEGF level in �lood serum 
of LLC­�­�earing mice that was o�served at �st day after 
tumor cell inoculation�� markedly slowed down. �uch 
deceleration was reflected in the parameter β�� the value 
of which was �y 6�% lower �р < �.���� for LLC­� group 
than that for LLC­ and LLC­��­�earing animals.
Relation between the level of circulating VEGF 
and indexes of growth and metastasis of LLC, 
LLC-9 and LLC-19. Analysis of correlation �etween 
the dynamics of change of the level of circulating VEGF 
and the dynamics of alteration of parameters of spread 
of tumor process has shown that independently on the 
Fig. 3. The correlations �etween values of tumor growth and metastatic spreading of LLC�� LLC­� LLC­�� in vivo and the dynamic 
changes of the level of circulating VEGF in tumor �earing mice
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degree of progression �resistance�� of Lewis lung carci­
noma�� the changes of VEGF levels in �lood serum of tu­
mor �earing animals statistically significantly correlated 
with increase of the num�er of lung metastases �Fig. 3��. 
The presence of correlation �etween the dynamics of 
VEGF alteration and the dynamics of change of other 
indexes of tumor process significantly depended on 
the degree of tumor resistance. In particular�� during 
the growth of LLC�� statistically significant correlation 
�etween VEGF level and the num�er of metastases in 
vascular phase has �een o�served�� �ut VEGF increase 
did not correlate nor with the increase of the volume of 
primary tumors�� nor with the changes in the volume of 
lung metastases. Contrary to LLC�� for LLC­� there has 
�een found a distinct correlation �etween the dynam­
ics of change of the level of circulating VEGF and the 
dynamics of change of the volume of primary tumors 
�R = �.�4�� p < �.����. It is necessary to note that sharp 
increase of the level of circulating VEGF at early stage 
of LLC­� stipulated a higher rate of the primary tumor 
growth as well as the shift of metastasis for earlier terms 
compared to that in parental LLC model. However�� at the 
terminal stage of LLC­� growth the maximal num�er of 
lung metastases was �y ��% lower �p < �.�5���� than that 
in LLC­�earing mice.
High statistically significant correlation �etween the 
dynamics of change of VEGF level and the dynamics of 
change of the studied indexes of tumor spread �volume 
of primary tumor�� the num�er of metastases�� volume 
of lung metastases�� the part of metastases at vascular 
phase�� was registered only for LLC­�� ­ Lewis lung car­
cinoma with high degree of resistance to cis­DDP.
�o�� one may conclude that elevation of the level of 
circulating VEGF upon tumor growth may serve as a 
marker of metastasis independently of the degree of 
tumor’s sensitivity to the action of cis­DDP. The direct 
correlation �etween the level of circulating VEGF and 
all studied indexes of the spread of tumor process 
�including volume of primary tumor and volume of lung 
metastases�� is o�served upon the growth of the tumor 
with high degree of drug resistance. 
One should note that LLC progression toward for­
mation of the resistance to cis­DDP was accompanied 
�y non­monotonous alterations of �oth angiogenic 
and metastatic potential. There were a�sent the direct 
correlations �etween the level of VEGF production �y 
tumor cells�� the level of circulating VEGF at terminal 
stage of tumor growth and indexes of metastasis of 
Lewis lung carcinoma with different sensitivity to the 
action of cis­DDP �Fig. 4��. 
The most interesting finding of the present research 
was the decrease of metastatic potential of LLC re­
vealed at early stages of formation of drug resistance 
�LLC­���. Despite unexpectedness of the o�tained re­      
sult�� it may �e caused �y phenomenon of domination 
of metastatically active cells [�3]. It is known that the      
process of domination of metastatically active cells in 
primary tumor is taking place �efore an appearance   
of distant metastases. Two �iologic properties of cells      
�high proliferative activity and high migration a�ility�� 
providing domination of tumor cell su�populations are 
known; metastatically active cells are characterized 
�y elevated migration activity upon the �ackground 
of relatively low proliferative activity [�4]. High rates   
of growth of primary tumors revealed at stage � 
of LLC progression�� are decreasing the chance of 
metastatically active cells to overgrow non­metastatic 
su�populations�� thus cousing�� possi�ly�� the decrease 
of tumor’s metastatic potential. At the same time�� an      
increased level of VEGF production �y LLC­� cells at   
the �ackground of its decreased metastatic potential 
is not corresponding to the statements that tumor 
angiogenesis promotes tumor progression�� and that’s 
why should �e studied in additional experiments . 
Fig.4. The level of circulating VEGF and tumor growth characte­
ristics at the �8��� days of LLC�� LLC­� and LLC­�� growth
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ИЗМЕНЕНИЯ УРОВНЯ VEGF И ПОКАЗАТЕЛЕЙ РОСТА 
И МЕТАСТАЗИРОВАНИЯ КАРЦИНОМЫ ЛЬЮИС В ПРОЦЕССЕ 
ЕЕ ПРОГРЕССИИ В НАПРАВЛЕНИИ ФОРМИРОВАНИЯ 
РЕЗИСТЕНТНОСТИ К CIS-DDP
Цель: изучить взаимосвязь между ангиогенным потенциалом опухоли и распространенностью опухолевого процесса на 
модели карциномы Льюис разной степени резистентности к действию cis-DDP. Методы: в работе использовали карциному 
легкого Льюис (LLC), а также два ее варианта (LLC-9 и LLC-19), полученные на 9-м и 19-м �тапе �кспериментальной                
прогрессии LLC в направлении �ормирования резистентности к cis-DDP       in vivo . Ангиогенный потенциал LLC, LLC-9 и   
LLC-19 оценивали иммуно�ерментным методом по уровню продукции VEGF первичными культурами   in vitro , а также по 
динамике изменений уровня циркулирующего VEGF в процессе роста LLC     in vivo. Результаты: прогрессивное снижение 
чувствительности LLC-9 и LLC-19 к действию cis-DDP, подтверждав�ееся       in vitro  (IC50 = 0,0077 ± 0,0005 мг/мл для 
LLC-9 и 0,0156 ± 0,0008 мг/мл для LLC-19 против 0,004 ± 0,0003 мг/мл для LLC,               p < 0,05) и   in vivo  (индекс торможения 
цитостатиком роста LLC-9 и LLC-19 cоставлял 26 и 3% соответственно против 46% для LLC; метастазирования — 46 и                
11% против 65% для LLC, p < 0,05), сопровождалось значительными изменениями ее ангиогенного потенциала. �ровень         
продукции VEGF in vitro  первичной культурой LLC-9 был в 1,5 раза вы�е (p < 0,05) по сравнению с таковым первичной       
культурой LLC, тогда как уровень продукции VEGF первичной культурой LLC-19 практически не отличался от такового              
для LLC. �ровень циркулирующего VEGF резко повы�ался уже на ранних �тапах роста LLC-9 и LLC-19              in vivo , тогда 
как у мы�ей с LLC динамика изменения его уровня характеризовалась длительным латентным периодом (t         lag = 17,0 ± 
0,3 сут). Характер изменений уровня циркулирующего VEGF в процессе роста LLC ( p < 0,001) коррелировал с количес-
твом метастазов; у животных с LLC-9 — с об�емом опухоли (     p < 0,01) и количеством (p < 0,05) метастазов. Несмотря 
на то, что максимальный уровень циркулирующего VEGF у мы�ей с LLC-9 значительно (p < 0,05) вы�е, чем у мы�ей с 
LLC, максимальное количество метастазов в легких у мы�ей с LLC-9 достоверно (p < 0,05) мень�е, чем у мы�ей с LLC. 
В отличие от LLC-9, в процессе роста LLC-19, сопровождав�егося  повы�ением уровня метастатического поражения 
легких (p < 0,05), уровень циркулирующего VEGF коррелировал как с об�емом опухоли (p < 0.01), так и с исследованными      
показателями метастазирования (p < 0.01).  Выводы: прямую корреляционную взаимосвязь между уровнем циркулирующего 
VEGF и изученными показателями распространенности опухолевого процесса выявляют ли�ь для опухолей с высокой             
степенью лекарственной резистентности, тогда как повы�ение уровня циркулирующего VEGF в процессе роста опухоли     
можно рассматривать в качестве маркера имеющихся метастазов независимо от степени ее резистентности. 
Ключевые слова: VEGF, карцинома легких Льюис, резистентность к cis-DDP.      
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